Homology Medicines to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Homology Medicines, Inc. (Nasdaq: FIXX) announced its participation in multiple upcoming virtual investor conferences. The events include:

• Cowen 42nd Annual Health Care Conference: Corporate Panel Discussion on Gene Editing, March 8, 12:50 p.m. ET.
• Oppenheimer 32nd Annual Healthcare Conference: Fireside Chat, March 16, 1:20 p.m. ET.
• H.C. Wainwright Gene Therapy and Gene Editing Conference: Available on-demand, March 30, 7:00 a.m. ET.

Webcast presentations will be accessible on the company's website for 90 days.

BEDFORD, Mass., March 03, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today participation at the following virtual investor conferences:

• Cowen 42nd Annual Health Care Conference:
  • Corporate Panel Discussion – Gene Editing: March 8 at 12:50 p.m. ET

• Oppenheimer 32nd Annual Healthcare Conference:
  • Fireside Chat: March 16 at 1:20 p.m. ET

• H.C. Wainwright Gene Therapy and Gene Editing Conference:
  • Available on-demand March 30 at 7:00 a.m. ET

The webcast presentations from the investor conferences will be accessible on Homology’s website in the Investors section, and the webcast replays will be available on the website for 90 days following the presentations.

About Homology Medicines, Inc.
Homology Medicines, Inc. is a clinical-stage genetic medicines company dedicated to transforming the lives of patients suffering from rare diseases by addressing the underlying cause of the disease. Homology’s clinical programs include HMI-102, an investigational gene therapy for adults with phenylketonuria (PKU); HMI-103, a gene editing candidate for PKU; and HMI-203, an investigational gene therapy for Hunter syndrome. Additional programs focus on metachromatic leukodystrophy (MLD), paroxysmal nocturnal hemoglobinuria (PNH) and other diseases. Homology’s proprietary platform is designed to utilize its family of 15 human hematopoietic stem cell-derived adeno-associated virus vectors (AAVHSCs) to precisely and efficiently deliver genetic medicines in vivo through a gene therapy or nuclease-free gene editing modality, as well as to deliver one-time gene therapy to produce antibodies throughout the body through the GTx-mAb platform. Homology has a management team with a successful track record of discovering, developing and commercializing therapeutics with a focus on rare diseases. Homology believes its initial clinical data and compelling preclinical data, scientific and product development expertise, internal manufacturing capabilities and broad intellectual property position Homology as a leader in genetic medicines. For more information, visit
www.homologymedicines.com.

Company Contacts
Theresa McNeely
Chief Communications Officer
and Patient Advocate
tmcneely@homologymedicines.com
781-301-7277

Media Contact:
Cara Mayfield
Vice President, Patient Advocacy
and Corporate Communications
cmayfield@homologymedicines.com
781-691-3510

FAQ

What events is Homology Medicines (FIXX) participating in March 2022?

Homology Medicines is participating in the Cowen 42nd Annual Health Care Conference on March 8, the Oppenheimer 32nd Annual Healthcare Conference on March 16, and the H.C. Wainwright Gene Therapy and Gene Editing Conference on March 30.

When is the Cowen 42nd Annual Health Care Conference for FIXX?

The Cowen 42nd Annual Health Care Conference will be held on March 8, 2022, at 12:50 p.m. ET.

How can I access the presentations for Homology Medicines (FIXX)?

The presentations will be available on-demand on Homology's website for 90 days after the conferences.

What is the focus of Homology Medicines, Inc.?

Homology Medicines focuses on developing genetic therapies for rare diseases, including treatments for phenylketonuria and Hunter syndrome.

What are the dates for the H.C. Wainwright Conference related to FIXX?

The H.C. Wainwright Gene Therapy and Gene Editing Conference will be available on-demand starting March 30, 2022, at 7:00 a.m. ET.